| P2093 | author name string | Ursula Ravens | |
| | Erich Wettwer | |
| | Michael Knaut | |
| | Claire Poulet | |
| P2860 | cites work | Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle | Q22254804 |
| | Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation | Q24306905 |
| | Novel germline GJA5/connexin40 mutations associated with lone atrial fibrillation impair gap junctional intercellular communication | Q24310844 |
| | A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome | Q24316980 |
| | Transient receptor potential (TRP) channels and cardiac fibrosis | Q24625500 |
| | The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins | Q28235712 |
| | Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation | Q28245803 |
| | G protein regulation of potassium ion channels | Q28292042 |
| | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 |
| | A structural basis for drug-induced long QT syndrome | Q28344808 |
| | Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins | Q29620720 |
| | Computational mapping identifies localized mechanisms for ablation of atrial fibrillation | Q31103589 |
| | Molecular mechanism for an inherited cardiac arrhythmia | Q33173678 |
| | Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity | Q33780983 |
| | Synthesis of a stable form of tertiapin: a high-affinity inhibitor for inward-rectifier K+ channels | Q33881312 |
| | TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation | Q34008101 |
| | Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties | Q34339876 |
| | The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation | Q34473254 |
| | Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics | Q34534868 |
| | Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. | Q34575287 |
| | Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. | Q34588710 |
| | Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. | Q34609020 |
| | Electrical, contractile and structural remodeling during atrial fibrillation | Q34682882 |
| | Genetics of atrial fibrillation: implications for future research directions and personalized medicine | Q34710843 |
| | Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats | Q34721297 |
| | Recent advances in the molecular pathophysiology of atrial fibrillation. | Q35142870 |
| | Remodeling of cardiomyocyte ion channels in human atrial fibrillation | Q35186203 |
| | Atrial fibrillation: current knowledge and future directions in epidemiology and genomics | Q35526930 |
| | Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. | Q35741443 |
| | Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol | Q35897567 |
| | A common polymorphism in SCN5A is associated with lone atrial fibrillation | Q35914701 |
| | A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression | Q36411369 |
| | Late sodium current in failing heart: friend or foe? | Q36496273 |
| | KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia | Q36692867 |
| | Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation | Q36842497 |
| | Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation | Q36909069 |
| | Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches | Q37178627 |
| | Pathophysiology and pharmacology of the cardiac "late sodium current.". | Q37228932 |
| | New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value | Q37231704 |
| | Atrial-selective sodium channel block for the treatment of atrial fibrillation. | Q37494653 |
| | Animal models for atrial fibrillation: clinical insights and scientific opportunities. | Q37624219 |
| | Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides | Q37639916 |
| | Antiarrhythmic therapy in atrial fibrillation | Q37771979 |
| | Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications | Q37821136 |
| | Pathophysiological mechanisms of atrial fibrillation: a translational appraisal | Q37830200 |
| | Novel molecular targets for atrial fibrillation therapy | Q37998312 |
| | The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities | Q38003030 |
| | Rotors and the dynamics of cardiac fibrillation | Q38085529 |
| | Electromechanical studies of an Anemonia sulcata toxin in mammalian cardiac muscle | Q39132880 |
| | Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor | Q39201888 |
| | Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide | Q40010953 |
| | Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs | Q40110329 |
| | Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel | Q40246665 |
| | A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation | Q40416086 |
| | Classification of antidysrhythmic drugs | Q40511657 |
| | Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes | Q40633399 |
| | Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. | Q41543002 |
| | Can inhibition of IKur promote atrial fibrillation? | Q41880477 |
| | Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation | Q42459986 |
| | Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells | Q42630302 |
| | Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium | Q43058171 |
| | Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine | Q43196284 |
| | Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. | Q43648748 |
| | Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action poten | Q43803581 |
| | Characterization of the sodium current in single human atrial myocytes | Q44230496 |
| | Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation | Q45101337 |
| | MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans | Q45805817 |
| | A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation | Q46311436 |
| | Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts | Q46885884 |
| | Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation | Q48684954 |
| | Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. | Q51461497 |
| | Sodium current in isolated human ventricular myocytes. | Q51654515 |
| | Novel anti-arrhythmic drugs for atrial fibrillation management. | Q53541090 |
| | Spread of excitation from the atrium into thoracic veins in human beings and dogs | Q54544168 |
| | Properties of a time-dependent potassium current in pig atrium: evidence for a role of kv1.5 in repolarization. | Q54586937 |
| | 2012 focused update of the ESC Guidelines for the management of atrial fibrillation | Q57312493 |
| | IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation | Q61937206 |
| | Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence | Q68447410 |
| | Evidence for two components of delayed rectifier K+ current in human ventricular myocytes | Q71089385 |
| | Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters | Q71853043 |
| | Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms | Q72256460 |
| | Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents | Q72560512 |
| | Differences between outward currents of human atrial and subepicardial ventricular myocytes | Q73020161 |
| | Ionic mechanisms of electrical remodeling in human atrial fibrillation | Q73311823 |
| | Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization | Q73532264 |
| | Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies | Q73581990 |
| | Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria | Q74439046 |
| | Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange | Q79421069 |
| | Association of human connexin40 gene polymorphisms with atrial vulnerability as a risk factor for idiopathic atrial fibrillation | Q80422539 |
| | Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias | Q83058608 |
| | Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation | Q83844154 |
| | The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation | Q85938541 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 4087-4097 | |
| P577 | publication date | 2013-06-03 | |
| P1433 | published in | Journal of Physiology | Q7743612 |
| P1476 | title | Atrial selectivity of antiarrhythmic drugs | |
| P478 | volume | 591 | |